Cargos activos de Sander van Berkel
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
SynAffix BV
 SynAffix BV BiotechnologyHealth Technology SynAffix BV develops next-generation antibody-drug conjugates for targeted cancer and other diseases. The application of the firm?s proprietary GlycoConnect technology, comprising precision modification of a protein's native glycosylation site, allows the fast and simple construction of antibody-drug conjugates that are both stable and homogeneous. The company was founded by Floris van Delft and Sander van Berkel in 2010 and is headquartered in Oss, the Netherlands. | Director Técnico/Científico/I+D | 01/01/2010 | - |
| Fundador | 01/01/2010 | - |
Historial de carrera de Sander van Berkel
Formación de Sander van Berkel.
| Radboud University Nijmegen | Graduate Degree |
Estadísticas
Internacional
| Países Bajos | 3 |
Operativa
| Chief Tech/Sci/R&D Officer | 1 |
| Founder | 1 |
| Graduate Degree | 1 |
Sectorial
| Health Technology | 2 |
| Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas privadas | 1 |
|---|---|
SynAffix BV
SynAffix BV BiotechnologyHealth Technology SynAffix BV develops next-generation antibody-drug conjugates for targeted cancer and other diseases. The application of the firm?s proprietary GlycoConnect technology, comprising precision modification of a protein's native glycosylation site, allows the fast and simple construction of antibody-drug conjugates that are both stable and homogeneous. The company was founded by Floris van Delft and Sander van Berkel in 2010 and is headquartered in Oss, the Netherlands. | Health Technology |
- Bolsa de valores
- Insiders
- Sander van Berkel
- Experiencia
